{"id":46739,"title":"DPP4","title_html":"<p>DPP4<\/p>","image":{"source":"https:\/\/www.protocols.io\/img\/default_protocol.png","placeholder":"https:\/\/www.protocols.io\/img\/default_protocol.png"},"doi":"dx.doi.org\/10.17504\/protocols.io.brvtm66n","doi_status":2,"uri":"dpp4-brvtm66n","type_id":4,"template_id":3,"published_on":1611807600,"parent_protocols":[],"parent_collections":[],"cited_protocols":[],"version_id":0,"version_data":{"id":"0","code":"brvtm66n","parent_id":0,"parent_uri":null,"is_same_owner":false,"has_pending_merge_request":false,"has_approved_merge_request":false},"created_on":1611806816,"modified_on":null,"categories":null,"public":1,"is_unlisted":0,"creator":{"name":"thananda ","affiliation":null,"affiliations":[],"username":"m4ule122s1v4ule1","note":null,"link":null,"image":{"source":"\/img\/avatars\/011.png","placeholder":"\/img\/avatars\/011.png"},"badges":[{"id":2,"image":{"source":"\/img\/badges\/bronze.svg","placeholder":"\/img\/badges\/bronze.svg"},"name":"Author"}],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},"journal":null,"journal_name":null,"journal_link":null,"article_citation":null,"has_versions":0,"link":null,"total_collections":0,"number_of_steps":0,"authors":[{"name":"thananda ","affiliation":"Navamindradhiraj University","affiliations":[],"username":"m4ule122s1v4ule1","note":"","link":null,"image":{"source":"\/img\/avatars\/011.png","placeholder":"\/img\/avatars\/011.png"},"badges":[],"verified":1,"is_verified_user":true,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false}],"versions":[],"groups":[],"is_owner":1,"has_subprotocols":0,"is_subprotocol":0,"is_bookmarked":0,"can_claim_authorship":0,"can_accept_authorship":0,"can_be_copied":1,"can_remove_fork":1,"fork_id":null,"url":"https:\/\/www.protocols.io\/view\/dpp4-brvtm66n","forks_count":{"private":0,"public":0},"access":{"can_view":1,"can_remove":0,"can_add":0,"can_edit":0,"can_publish":0,"can_get_doi":0,"can_share":1,"can_move":1,"can_move_outside":1,"can_transfer":1,"can_download":1,"is_locked":0},"guid":"3068A690611E11EB97B941DAC5CECD6D","state_version_id":21,"steps":[],"document":"<div class = \"text-blocks\"><div class = \"text-block\">Sample Size Calculation:<\/div><div class = \"text-block\">Choi et alreported the reduction of reactive oxygen species(NADPH Oxidase,NOX 4) by gemigliptin for 340units. By using independent formula with related samples, therefore <\/div><div style = \"text-align :; float : ;\"><img style = \"\" src = \"\" \/><\/div><div class = \"text-block\">     Z\u03b1 =Z value atlevel of significance 0.05 = 1.960<\/div><div class = \"text-block\">     Z\u00df= Z value at level of significance (0.2)=0.840<\/div><div style = \"text-align :; float : ;\"><img style = \"\" src = \"\" \/><\/div><div class = \"text-block\">     2d =Variance of reactive oxygen species before and after gemigliptin treatment<\/div><div class = \"text-block\">     M1-M0 = Difference of reactive species before and after gemigliptin treatment      =340<\/div><div class = \"text-block\">     n =<\/div><div style = \"text-align :; float : ;\"><img style = \"\" src = \"\" \/><\/div><div class = \"text-block\">     n=100<\/div><div class = \"text-block\">Since this is the first study for gemigliptin for this outcome,the target number of enrolled pateintswas set at 100 <\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Reference:<\/span><\/div><div class = \"text-block\">Choi S,Ryu H,Oh E,Choi J,Cho J,Kim C,Kim Y,Park S.Dipeptidyl peptidase 4 inhibitor gemigliptin protevts against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cell. PLos One 2017;12(7):e0180393<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Method of randomization<\/span><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:left\">After enrollment, eligible patients will be randomized (1:1) by systemic random samplingby the study coordinator to either gemigliptin or control group,using envelop containing letter A or B , 2 of each letter in one envelop.Therefore one envelop will have 2 pairs of each letter such ,ABAB or BABA while A represents gemigliptin and B means control.The patients were blinded to the allocation.Only the predesigned study person will have access to the sealed randomization. <\/div><\/div><\/div>","materials":[],"description":"","changed_on":1611807600}